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Abstract. The present study aimed to measure the improve-
ment in pain relief and quality of life in patients with osteolytic 
solitary painful bone metastasis treated by cryoablation (CA) 
or radiofrequency ablation (RFA). Fifty patients with soli-
tary osteolytic painful bone metastases were retrospectively 
studied and selected by propensity analysis. Twenty-five 
patients underwent CA and the remaining twenty‑five under-
went RFA. Pain relief, in terms of complete response (CR), 
the number of patients requiring analgesia and the changes in 
self-rated quality of life (QoL) were measured following the 
two treatments. Thirty-two percent of patients treated by CA 
experienced a CR at 12 weeks versus 20% of patients treated 
by RFA. The rate of CR increased significantly with respect 
to baseline only in the group treated by CA. In both groups 
there was a significant change in the partial response with 
respect to baseline (36% in the CA group vs. 44% in the RFA 
group). The recurrence rate in the CA and RFA groups was 
12% and 8%, respectively. The reduction in narcotic medica-
tion requirements with respect to baseline was only significant 
in the group treated by CA. A significant improvement in 
self-rated QoL was observed in both groups. The present study 
seems to suggest that CA only significantly improves the rate 
of CR and decreases the requirement of narcotic medications. 
Both CA and RFA led to an improvement in the self-rated QoL 
of patients after the treatments. However, the results of the 
present study should be considered as preliminary and to serve 
as a framework around which future trials may be designed.
Introduction
Metastases are the major cause of cancer-associated death in 
cancer patients, and are the predominant sites to which metas-
tasis occurs (1,2,3). The primary tumors that most frequently 
metastasize to the bones include breast, prostate and lung 
cancer (4-6). Pain is the most common symptom experienced 
by patients, among all potential complications associated with 
bone metastasis, and results in a significant deterioration in 
quality of life (QoL) (1,4,5,7,8). Current treatment objectives 
are designed to decrease the tumor burden in patients with 
overt bone metastases, maximize pain control and reduce 
the incidence of skeletal-related events (5). Pain manage-
ment/analgesia, surgery, radiation therapy (RT), systemic 
therapy, or a combination of these techniques are current 
strategies for the management of skeletal metastasis (9). 
However, the long-term results of these treatments require 
improvement (10,11).
Thermoablation is a category of non-surgical approaches 
used to treat otherwise unresectable tumors, and the techniques 
it includes utilize a variety of power sources. Furthermore, an 
array of delivery methods for ablation exist, including laser 
ablation, radiofrequency ablation (RFA), cryoablation (CA), 
microwave ablation and high intensity focused ultrasound 
(HIFU) (12-14). These techniques have proven to be useful 
therapeutic options for bone tumor management, in addition 
to the treatment of metastatic liver and malignant primary 
tumors for which they were originally developed (15-18). 
Recent studies have demonstrated that the association of RT 
with RFA is well tolerated, and has a satisfactory profile of 
adverse side effects (19,20). The aim of the present study 
was to investigate whether RFA and CA improve the clinical 
management of osteolytic solitary painful bone metastases, 
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selecting the study population retrospectively by propensity 
analysis.
Materials and methods
Patient selection. In the present study, patients >18 years, 
with painful solitary osteolytic bone metastases, confirmed 
by radiological and histological investigations were retrospec-
tively selected from a pool of subjects who underwent CA or 
RFA between September 2011 and September 2014. Magnetic 
resonance imaging (MRI) examination, computed tomog-
raphy (CT), and nuclear isotope (technetium 99) bone scans 
were performed within the 4 weeks prior to the procedures. 
Eligibility criteria included: (i) A pain score of ≥5 on the vali-
dated visual analog scale (VAS) over the previous 24 hours (or 
a score of <5 with the use of narcotic medications); (ii) pain 
localized to the site of the bone metastases; (iii) life expectancy 
>3 months, and (iv), a Karnofsky performance status (KPS) 
score >70. Exclusion criteria were: (i) The area of pain had been 
previously treated with RT, palliative surgery or interventional 
radiological approaches; (ii) radiographic evidence of spinal 
cord or cauda-equina compression; (iii) lesions positioned 
within 0.5 cm of a critical site, such as the spinal cord, brain, 
aorta, inferior vena cava, bowel, or bladder; (iv) abnormal 
fracture of the treatment site. Written informed consent was 
obtained from all patients. The present retrospective study was 
approved by the San Salvatore Hospital institutional Ethical 
Committee.
Cryoablation. Percutaneous CA was carried out under 
conscious sedation with an argon-based cryotherapy system 
(SeedNet® Gold Cryoablation System, Galil Medical Ltd., 
Yokneam, Israel). Following sterile preparation, one or more 
cryoprobes (IceRod®, Galil Medical Ltd.) were introduced into 
the target lesion with CT guidance by experienced radiologists. 
The cryoprobes were introduced in a parallel arrangement 
~2 cm apart. For larger lesions, a cluster of cryoprobes was 
placed within 1 cm of the tumor margin to provide adequate 
coverage of the outer border of the target lesion. Cryoprobe 
positioning was confirmed by CT imaging. Rapid freezing of 
the target lesion (‑100 ˚ C within a few seconds) was performed, 
and two 15 min freezes separated by a 10 min thaw were used 
at each cryoprobe position.
Radiofrequency ablation. Percutaneous RFA was performed 
under conscious sedation. Following sterile preparation, a 
LeVeen™ needle electrode (Boston Scientific Corp., Natick, 
MA, USA) was introduced under CT guidance into the metas-
tases. After unfolding the electrode tines into the metastases, 
the needle was connected to a radiofrequency generator (RF 
3000®; Boston Scientific Corp.). The procedure was conducted 
according to the protocols supplied by the equipment manu-
facturers. Briefly, the developed energy was increased 10 W 
every 3 min up to 90 W, until tissue impedance increased and 
further current flow was prevented (roll‑off). A target intratu-
moural temperature higher than 60 ˚C was considered as an 
indicator of adequate thermocoagulation. A single ablation 
was performed for lesions measuring <3 cm in the longest 
diameter. For larger lesions (3-7 cm) a cluster RFA electrode 
technique was used (3 needles spaced 5 mm apart). At the end 
of each CA or RFA, a CT was performed to ensure that the 
extent of ablation was confined to the target tissue and that 
there was no substantial damage in the tissue surrounding the 
target. After all combined procedures, patients were observed 
for 2 h in the recovery room and were then admitted to the 
hospital for a minimum of 24 h.
Patient assessment. A full physical examination was performed 
and data on direct and indirect changes in pain levels were 
assessed by VAS and a medication level questionnaire. QoL 
was assessed with a single question from the McGill Quality 
of Life Questionnaire (MQOL) (21). The strongest evidence of 
validity comes from comparison with the single-item quality 
of life measure (21).
Complications of the procedures. Complications related to 
ablative approaches were rated as major or minor according 
to the guidelines of the Society of Interventional Radi-
ology (22).
Study endpoints and response criteria. The primary endpoints 
were to assess the changes from baseline (pre-CA or RFA) to 
week 12 in the rate of (1) complete (CR) and (2) partial (PR) 
responses (23). The secondary endpoints were to assess the 
changes from baseline (pre-CA or RFA) to week 12 in the 
rate (1) of subjects requiring opioid analgesic use and (2) in 
self-experienced QoL.
Statistical analysis. The data analyzed in the present study 
were derived from a population-based retrospective study. 
In order to reduce treatment selection bias and realistically 
determine the treatment effects, a case control-matched 
propensity analysis was performed. Multivariate logistic 
regression was used to calculate the predicted probability of 
the dependent variables, as well as the propensity score for all 
observations in the dataset. The dependent variables included 
in the multivariate analysis were age, KPS, primary tumor 
number, metastasis location, VAS scale, and the QoL prior 
to the procedures. A 1:1 matched analysis was performed, 
where one subject treated by CA was matched to one subject 
treated by RFA. Continuous variables not normally distrib-
uted (Shapiro-Wilk test) were presented as medians and 95% 
confidence intervals (95% CI). The Mann‑Whitney U test 
was used to evaluate the difference between two groups and 
the Kruskal-Wallis test was used to evaluate the difference 
between more than two tests. If the Kruskal-Wallis test was 
statistically significant, a pairwise comparison of subgroups 
was performed according to Conover. Dichotomous variables 
were summarized by absolute and/or relative frequencies. The 
Chi-squared test or Fisher's exact test was used to evaluate the 
difference between two groups. For multiple comparisons, 
the alpha value threshold was adjusted by using Bonferroni 
correction. For matched pairwise multiple comparisons, 
dichotomous variables were compared with Cochran's Q 
test. For matched pair-wise comparisons McNemar's test 
was used. All tests were two‑sided except where specified, 
and were determined by Monte Carlo significance. An alpha 
value threshold of 0.05 was used. All statistical analyses 
were performed using the SPSS® statistical analysis software 
package, version 10.0 (SPSS, Inc., Chicago, IL, USA).
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Results
Table I lists the clinical and demographic characteristics of 
treated patients stratified according to propensity score and 
treatment received. At 12 weeks following treatment, all 
patients were analyzed, as the selected patients were long-term 
survivors of a solitary bone lesion. The VAS scale before treat-
ments was 7 (95% CI, 5-7) in the group treated by RFA and 
7.5 (95% CI, 5-67.6) in the group treated by CA. The mean 
tumor size was 4 cm in both groups. Primary tumor lesions 
were located in lung, prostate, kidney, colorectum and breast, 
and the metastatic sites were pelvis, sacrum, rib, vertebrae, 
humerus and femur (Table I). Eight out of 25 subjects treated 
by CA (32%) experienced a CR at 12 weeks vs. 5 out of 
25 patients treated by RFA (20%) (Fig. 1). Interestingly, when 
within analysis was performed by the Cochran's Q test, the 
rate of CR in the CA group significantly increased with respect 
to the baseline (Fig. 1C). By contrast, this parameter did not 
significantly increase with respect to baseline in the RFA 
group (Fig. 1B). Nine out of 25 subjects treated by CA (36%) 
experienced a PR at 12 weeks vs. 11 out of 25 of patients treated 
by RFA (44%) (Fig. 1). In both groups there was a significant 
change in the PR with respect to baseline (Fig. 1 C and D). 
The number of subjects with stable or progressive pain was 
8 out 25 (32%) in the CA group and 9 out of 25 (36%) in the 
RFA group. Three out of 8 (37.5%) patients in the RFA group 
and 2 out of 9 (22%) patients in the CA group with stable or 
progressive pain at 12 weeks from treatments, experienced 
a 3‑point fall in pain within the first 2 weeks following the 
procedure. These patients had recurrent pain of intensity equal 
to or greater than the worst pain experienced prior to CA or 
RFA treatments between the 6th and 10th of follow-up, with 
no difference in the temporal trend between the two groups. 
All patients received oral narcotic analgesia over the month 
Table I. Clinical characteristics according to propensity score
Characteristics RFA (n=25) CA (n=25) P-value
Age, years (range) 66 (59-70) 67.5 (64.4 to 70.6) 0.678a
VAS scale (range) 7 (5-7) 7.5 (5-7.6) 0.822a
Sex, no. (%)
  Male 11 (44) 12(48) 1.0c
  Female 14 (56) 13 (52)
KPS, no. (%)
  91-100 10 (40) 11 (44) 1.0b
  70-89 15 (60) 14 (56)
Tumor size, cm 4 (4-5) 4 (3.4-6) 0.456a
Primary tumors, no. (%)
  Lung cancer 7 (28) 7 (28)
  Prostate cancer 2 (8) 3 (12)
  Renal cancer 3 (12) 4 (16) 0.79b
  Colorectal cancer 4 (16) 2 (8)
  Breast cancer 14 (56) 9 (36)
Metastasis location, no. (%)
  Pelvis 10 (40) 8 (32)
  Sacrum 6 (24) 7 (28)
  Rib 2 (8) 2 (8) 0.99b
  Vertebrae 3 (12) 4 (16)
  Humerus 2 (8) 2 (8)
  Femur 2 (8) 2 (8)
Medical systemic treatments, no. (%)d
  Bisphosphonates 5 (20) 8 (32) 0.52c
  Narcotic analgesics 25 (100) 25 (100) 1.0b
  Hormonal therapy 9 (36) 8 (32) 1.0c
  Chemotherapy 18 (72) 15 (60) 0.55b
  Immunotherapy 2 (8) 4 (12) 0.67c
In post hoc pairwise comparisons of subgroups, the alpha error was set at 0.016 according to Bonferroni correction. aKruskal-Wallis test; 
bChi-Squared test; cFisher's Exact test; dthe sum of percentage in each group is >100%, since patients may undergo more than one systemic 
treatment. KPS, Karnofsky performance status; Medians and CI95%; RFA, Radiofrequency Ablation; CA, Cryoablation.
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prior to treatment with CA or RFA (Table I). At 12 weeks, 
20% of patients (5/25) in the RFA group and 36% of patients 
(9/25) in the CA group did not require narcotic medication 
(Fig. 2). For data on the complete and partial response, the 
McNemar test indicated that the reduction in narcotic medi-
cation requirements was significantly reduced in the CA 
group (P=0.0039), whereas in the RFA group, there was a 
trend toward a lower rate of narcotic used that did not reach 
statistical significance (P=0.062). The higher rate of CR and 
PR observed in patients treated with CA or RFA correlated 
with an improved self-rated QoL (Fig. 3). At 12 weeks, patients 
treated by CA or RFA reported a significant improvement 
in self-rated QoL. In the group treated by CA, the MQOL 
score increased from 3.9 [interquartile range (IRQ) 3-4] to 
6.1 (IRQ 5.2-8) whereas in the group treated by RFA the score 
increased from 3.6 (IRQ 3.1-4.2) to 5.6 (IRQ 4.3-7) (Fig. 3). 
Overall, patients tolerated the CA and RFA treatment. Two 
transient nerve injuries occurred, one in the RFA group and 
one in the CA group, neither of which prolonged the length of 
hospitalization. These injuries appeared 6 and 11 days after 
the CA and RFA treatments, respectively, with improvement 
within 10 days following administration of a systemic steroid.
Discussion
Interventional radiologists have developed a number of abla-
tive techniques for the management of a range of different 
clinical presentations, including bone metastatic disease, 
with outstanding results in terms of their efficacy. A rela-
tively limited number of studies have investigated the RFA 
in the management of metastatic bone lesions. In a previous 
study, RFA produced a significant reduction in pain, and a 
significant improvement in the relief felt and in mood, when 
assessed at one and three months following treatment (16). 
Another feasibility study confirmed the analgesic efficacy of 
RFA in absence of serious complication (15). A multicentre 
trial conducted on 43 patients with painful, refractory, pelvic 
or sacral lesions evaluated RFA (13). At 4, 12 and 24 weeks 
following RFA, 95% of treated patients reported pain relief (a 
fall of at least two points in the most intense pain) with a reduc-
tion in the provision of analgesics observed at 8 and 12 weeks. 
Complications included cutaneous burn, transitory faecal and 
urinary incontinence following treatment of a sacral location, 
and an acetabular fracture. CA is a common ablative technique 
that creates an ̔ice-ball̓  deep in bone by using miniaturized 
Figure 1. (A) Percentage of subjects experiencing Complete Response (CR) and Partial Response (PR) after CA and RFA treatments. Within groups assessment 
measured at baseline and 12 weeks after treatments. Pairwise multiple comparisons by Cochran's Q test for (B) Radiofrequency ablation and (C) cryoablation. 
CA, cryoablationl RFA, radiofrequency ablation.
  A
  B   C
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Figure 3. Quality of life score measured by a single question from the MQOL. Within groups assessment of self rated QoL measured at baseline and 12 weeks 
after treatments. MQOL, McGill quality of life questionnaire; QoL, quality of life, CA, cryoablation; RFA, radiofrequency ablation.
Figure 2. Percentage of patients requiring narcotic medications following CA and RFA treatments. Within groups, assessment was measured at baseline and 
12 weeks after treatments by the McNemar test. CA, cryoablationl RFA, radiofrequency ablation.
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argon-gas devices. This method is associated with reduced peri- 
and post-procedural pain. Recently Callstrom et al (24,25) 
performed clinical trials in which percutaneous CA was used 
for the palliation of painful metastatic lesions, and the results 
demonstrated that CA was safe and effective at reducing the 
pain associated with metastatic lesions. To date, the precise 
mechanisms through which CA followed by RT can relieve 
symptomatic pain remains to be elucidated fully. Pain expe-
rienced by patients suffering from bone metastases may have 
several pathophysiological mechanisms. These include: (i) 
Microfractures by direct metastatic bone invasion; (ii) peri-
osteum distortion resulting from increased pressure on the 
endosteum; (iii) nerve-root compression or muscle spasm; and 
(iv) release of chemical mediators involved in the conduction 
of nociceptive signals towards the central nervous system (2,3). 
Reduced cancer cell burden within bone tissue is associated 
with endosteal pressure reduction. The release and modulation 
of pain-related chemical mediators with combination treatment 
may significantly affect the perception of pain intensity. 
The current study performed a comparative analysis of the 
effects that CA or RFA (two well-known interventional abla-
tive approaches) have in relieving cancer pain related to bone 
metastasis. To the best of our knowledge, this is the first report 
that analyzes the clinical performances of both RFA and CA 
in patients with bone metastatic lesions. Of note, the response 
criteria were defined according to the endpoint criteria of the 
International Bone Metastases Working Party guidelines on 
palliative radiotherapy endpoints for future clinical trials. Thus, 
the results of the present study are comparable with the literature 
that used the same criteria. Furthermore, the response criteria 
included changes in narcotic medication use and self-rated QoL 
data. Our retrospective study design was based on estimates of 
propensity scores, which can facilitate the generation of unbiased 
treatment effect estimates. This powerful statistical approach 
was coupled with the use of a pre- and post-test experimental 
design. This experimental design is an attractive model for the 
assessment of clinical efficacy before and following a treatment, 
as the comparisons were made ‘within subjects’ rather than 
‘between subjects’. An important consequence of this experi-
mental strategy is that the study power is greatly improved 
compared to other research designs.
The present study demonstrated that CA significantly 
improved both CR and PR with respect to baseline at 12 weeks 
following ablation. By contrast, only PR significantly improved 
with respect to baseline following RFA treatment. These data 
were in line with the improvement of self-rated QoL observed 
in patients treated by CA or by RFA. When self-rated QoL 
was assessed from baseline to 12 weeks, the patients treated by 
the two ablative techniques experienced improved QoL, and 
this difference was statistically significant. These data are also 
paralleled with the results demonstrating that 20% of subjects 
treated by RFA and 32% of patients treated by CA reported 
no opioid analgesic use at 12 weeks. Interestingly, in terms of 
medical adjunctive treatment, all subjects took narcotic medi-
cations prior to treatment. The data concerning the percentage 
of patients who did not use analgesic medication are in agree-
ment with a study by Callstrom et al (24), who reported that 
4 of 19 studied patients were not administered opioid analgesic 
following CA. Notably, and in agreement with literature, the 
rate of complications was 4% following both treatments.
The present study has several limitations, the major ones 
being the non-randomized study design and limited sample 
size. Large, randomized controlled clinical trials have provided 
strong evidence for the efficacy of therapeutic procedures or 
treatments. Any bias in these studies has been controlled by 
using a strategy based on propensity score analysis, which 
can generate groups of patients, randomized post-hoc for 
important clinical characteristics. The results of the present 
study have fewer methodological biases from using compara-
tive analysis by propensity-matched pairs, rather than other 
common statistical methods.
In conclusion, the results of the present study suggest 
for the first time that CA, in contrast to RFA, significantly 
improves the rate of CR and decreases the requirement of 
narcotic medications. Both CA and RFA improve PR and the 
self-rated QoL of patients following the treatments. However, 
our data should be considered as preliminary and to serve as a 
framework around which to design future trials.
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